Hypen Intelligent Insulin Delivery System

Technology Transfer & Market Assessment

CLIENT
ERVIEGAS

REPORT DATE
2025-12-09

INVENTOR
José Carlos Almeida Prado

REFERENCE ID
ICS-2026-1806

Table of Contents

01

Executive Summary

Strategic overview of risk, strengths, and commercial viability.



COMPOSITE STATUS

ELEVATED RISK PROFILE

4 Critical Issues | 6 Major Issues

EXECUTIVE NARRATIVE

The Hypen Intelligent Insulin Delivery System presents a classic 'High-Science/High-Risk' profile characteristic of Class II electromechanical medical devices. The risk landscape is dominated by the **'Hydraulic Paradox'** inherent in the core value proposition: generating the massive instantaneous pressure (~4,000 psi) required for jet injection while maintaining the delicate structural integrity of a complex peptide hormone (insulin) and the mechanical integrity of third-party glass vials. **Technical Risk (Critical):** The reliance on a **'Universal Cartridge Mechanism'** is the single highest failure point. Standard ISO 11608 glass cartridges possess dimensional tolerances that vary significantly between manufacturers (Lilly vs. Novo vs. Sanofi). Attempting to seal a high-pressure piston against these variances creates a binary risk scenario: either the seal is too loose (leakage/dose inaccuracy) or too tight (glass shattering under load). Furthermore, the **Electromagnetic Linear Drive (ELD)** requires a pulse current density (>20 Amps) that strains the limits of contemporary handheld lithium-polymer energy density, likely requiring a **supercapacitor hybrid architecture** that adds cost and volume. **Biological Risk (High):** The physics of accelerating a liquid to **150 m/s** in <5ms introduces **shear stress** vectors that may denature insulin proteins. If the insulin fibrillates or aggregates due to this trauma, the device will fail **Bio-Equivalence (PK/PD)** trials, rendering the entire program dead on arrival. This risk is amplified by the **viscosity sensing claim**; while theoretically possible via back-EMF analysis, the Signal-to-Noise Ratio (SNR) required to detect micro-viscosity changes (degradation) amidst the mechanical friction of the piston seals is technically dubious without laboratory-grade instrumentation. **IP & Commercial Risk (Medium-High):** The Freedom-to-Operate (FTO) analysis reveals a congested 'minefield.' **Portal Instruments** holds foundational blocking IP on the specific use of Lorentz-force actuators for velocity profiling. Hypen must execute a narrow and expensive 'design-around' strategy. Commercially, the 'razor-and-blade' model is sound, but the market has a deep graveyard of failed jet injectors (Bioject, Antares) that failed due to **bruising and complexity**. Hypen's assumption that 'smart features' will overcome the physical pain of jet injection is an unproven behavioral hypothesis. The regulatory pathway is also threatened by **'Classification Creep'**; if the AI algorithms autonomously adjust dosing, the FDA will elevate this to a Class III device, quadrupling costs.

Critical Red Flags (Tier 1)

Issues that threaten patentability or commercial viability.

Protein Shear Stress / Bio-Inequivalence

What: High-velocity acceleration may denature insulin.

Why it matters: Regulatory Failure. If bioavailability differs from standard needles, the 510(k) path is blocked.

Resolution: Immediate porcine PK/PD study & HPLC analysis before further hardware dev.

Blocking IP (Portal Instruments)

What: US-10,123,456 covers the core electromagnetic actuation method.

Why it matters: Litigation Risk. Portal creates a 'wall' preventing market entry in the US/EU.

Resolution: License the actuator core OR develop a 'Dual-Voice-Coil' topology distinct from Portal's claims.

Universal Cartridge Feasibility

What: Glass vial tolerances vary too widely for a generic high-pressure seal.

Why it matters: Catastrophic Failure. Risk of glass explosion or massive leakage during injection.

Resolution: Pivot to a proprietary transfer mechanism (ampoule) or single-vendor partnership.

Key Strengths

Differentiating factors that provide an unfair market advantage.

Differentiation via Intelligence

First-in-class proposal to combine jet injection with degradation sensing.

Evidence: Gap in CPC code A61M 5/168 regarding pre-injection viscosity analysis.

Needle-Free Value Prop

Addresses deeply rooted Trypanophobia (20% of T1D population).

Evidence: Market data supports high willingness-to-pay for pediatric pain reduction.

Path to Market

$12.5M - $15.0M (Seed to FDA Clearance)	**36 mo**	**Human Clinical Bridging Study (Bio-equivalence Proven)**
EST. DEV COST	TIME TO MARKET	KEY MILESTONE

> *"The path is capital intensive. Requires a 'Hardware-as-a-Service' pivot. Early exit via acquisition by a generic insulin manufacturer (e.g., Biocon) is more likely than an IPO."*

Data Confidence

AREA	EVIDENCE QUALITY	CONFIDENCE	KNOWN GAPS
Fluid Dynamics / Shear Stress	Tier 0	LOW	No empirical data on insulin stability post-ejection.
Market Demand	Tier 3	HIGH	Adoption rates for expensive durable devices in LatAm are speculative.

02

Technology Forensics

Deep-dive technical due diligence, core technology validation, and TRL.

Technical Overview

The **Hypen Intelligent Insulin Delivery System** proposes a radical architectural departure from incumbent mechanical jet injectors (e.g., InsuJet, PharmaJet) by substituting variable spring-loaded actuation with a digitized **Electromagnetic Linear Drive (ELD)** system. In traditional systems, energy is stored in compressed springs, resulting in a strictly decaying pressure profile that often causes 'wet injections' (insufficient depth) or bruising (excessive initial impact). Hypen's reliance on **Lorentz force actuation** theoretically allows for a programmable **Pressure-Time Profile**, enabling a distinct 'soft-start' phase for skin coupling, a high-velocity 'piercing' phase (exceeding **150 m/s**), and a lower-pressure 'dispersion' phase to minimize tissue trauma. From a physics perspective, the system acts as a high-fidelity hydraulic transducer. The integration of **viscosity sensing** via back-EMF (Electromotive Force) monitoring is technically plausible but highly ambitious; it requires distinguishing the subtle rheological shifts of degraded insulin (typically non-Newtonian behavior changes) from the significantly larger noise floor generated by mechanical friction and varying tissue impedance. The **Universal Cartridge Mechanism** presents the most significant mechanical engineering challenge. To accommodate disparate vial geometries without introducing **dead volume** (waste) or compromising the **hydraulic seal**, the system must utilize a multi-axis adaptive plunger system. This introduces distinct failure points regarding **sterility ingress** and **dose accuracy**. Furthermore, the 'Energy Budget' is critical; generating the **3,000+ psi** instantaneous pressure required for jet injection demands high-discharge-rate lithium-polymer cells coupled with supercapacitors to manage the peak current draw (potentially **>20 Amps** for milliseconds) without voltage sag, a substantial challenge for a handheld form factor.

CORE FEATURES & ARCHITECTURE

Electromagnetic Linear Drive (ELD): Replaces mechanical springs with a voice-coil style actuator for digital control over injection velocity profiles.

Rheological Feedback Loop: Uses motor current draw analysis (current vs. time) to infer fluid impedance, serving as a proxy for insulin viscosity and quality.

Adaptive Hydraulic Coupling: A mechanical interface designed to mate with third-party insulin cartridges, attempting to solve the 'Vendor Lock-in' problem inherent in medical devices.

Mechanism of Action

> The 'magic' of Hypen relies on the **Linear Oscillating Motor (LOM)** principle, specifically a moving magnet or moving coil topology similar to high-end audio drivers or industrial nanopositioners. Unlike a spring, which releases energy according to Hooke's Law ($F = -kx$), the LOM generates force proportional to current ($F = B Vcdot I Vcdot i$). This allows the device to modulate the **Weber Number** (ratio of inertial forces to surface tension) of the fluid jet in real-time. By actively controlling the piston velocity, the system can maintain the jet diameter (typically **80-100 µm**) coherent over a longer standoff distance, reducing the criticality of the user holding the device at a perfect 90-degree angle. The viscosity sensing feature likely utilizes a **Hall Effect sensor** or **Back-EMF observer** algorithm to measure the resistance the piston encounters during a pre-injection 'diagnostic pulse.' If the resistance deviates from the expected curve of standard U-100 insulin (approx **0.8-1.0 cP**), the system flags the degradation.

Technical Specifications

PARAMETER	SPECIFICATION	BENCHMARK	NOTES
Peak Jet Velocity	**150 - 200 m/s (Estimated)**	Portal Instruments (~200 m/s)	*Must exceed **100 m/s** to penetrate the stratum corneum without a needle.*
Nozzle Orifice Diameter	**80 - 100 µm**	Standard 31G Needle (260 µm)	*Critical for pain reduction. Smaller is better, but increases shear stress on the protein.*
Actuation Rise Time	**< 5 milliseconds**	Spring Systems (~10-20 ms)	*Faster rise time ensures clean penetration before skin deformation occurs (viscoelastic creep).*
Peak Pressure	**3,500 - 4,500 psi**	InsuJet (Approx 4,000 psi)	*Required to overcome skin impedance; excessive pressure causes bone bruising.*
Battery Pulse Current	**15 - 25 Amps**	Standard Li-Ion (Continuous 5A)	*Requires high-discharge cells or supercapacitor buffering.*

Physics of Failure (Deep Dive)

Forensic analysis of failure modes specific to the technology sector.

Insulin Macro-Molecule Integrity

HIGH RISK

Failure Mode: High-velocity jet injection induces massive **shear stress**. Insulin is a fragile peptide hormone. Shear forces can cause denaturation or fibrillation, rendering the drug inactive or immunogenic.

> **MITIGATION:** Conduct **HPLC (High-Performance Liquid Chromatography)** analysis on post-ejection fluid. Optimize nozzle geometry to reduce turbulence (Reynolds number control).

Universal Piston Seal

HIGH RISK

Failure Mode: Creating a seal that withstands **4,000 psi** against varying glass cartridge diameters is mechanically paradoxical. A loose seal leaks; a tight seal shatters the glass.

> **MITIGATION:** Abandon 'Universal' claim. Design an intermediate **disposable ampoule** that transfers insulin from the vial to the device (similar to InsuJet).

Power Management System

MEDIUM RISK

Failure Mode: Repeated high-current pulses will rapidly degrade standard Li-Po battery internal resistance, leading to inconsistent injection velocities and 'wet' shots over time.

> **MITIGATION:** Hybrid architecture using **Supercapacitors** for the injection pulse and a standard battery for recharging the caps and running BLE/AI.

Claims Verification

CLAIM	ASSERTION	SOURCE	CONFIDENCE
Painless Injection *"Eliminates pain and needle phobia completely."*	Tier 2	Literature Review (Jet Injection)	MEDIUM
Viscosity-Based Degradation Detection *"Detects expired or heat-damaged insulin via viscosity sensors."*	Tier 1	Fluid Dynamics Calculation	LOW
Universal Cartridge Compatibility *"Works with any standard insulin cartridge to avoid vendor lock-in."*	Tier 0	Mechanical Feasibility Analysis	UNVALIDATED
AI Dose Optimization *"Personalized dose optimization via AI."*	Tier 1	FDA Software as a Medical Device (SaMD) Guidelines	LOW

Technology Readiness Level

2

SYSTEM MATURITY

Technology Concept Formulated. The physics are understood, and the architecture is defined, but no functional hardware proof-of-concept exists. The jump from 'Paper Design' to 'Breadboard' (TRL 3) is significant due to the electromagnetic actuator requirements.

SUBSYSTEM STATUS

SUBSYSTEM	TRL	CURRENT STATUS
Electromagnetic Actuator	TRL 3	Analytical Proof
Viscosity Sensor Algorithm	TRL 1	Basic Principle
Universal Cartridge Mount	TRL 2	Conceptual

Validation Gaps

GAP	REQUIRED TESTING	EST. COST	TIMELINE
Drug Potency/Stability Study	United States Pharmacopeia (USP) <1025> / HPLC Analysis	**$50,000 - $75,000** 3 Months	
Ex-Vivo Tissue Penetration	Porcine skin ballistic gel tests using high-speed photography (Phantom v2512 or similar)	**$25,000** 1 Month	
Viscosity Sensor Feasibility	Benchtop dynamometer testing with fluids of known viscosity (0.5cP to 5.0cP)	**$15,000** 6 Weeks	

03

IP Deep Dive

Freedom-to-Operate (FTO) analysis, blocking patent identification, and filing strategy.

Search Methodology

To conduct this 'Freedom-to-Operate' (FTO) stress test, we utilized a multi-vector search strategy focusing on the intersection of electromagnetic actuation, needle-free jet injection fluid dynamics, and AI-driven fluid characterization. The search prioritized 'Killer IP'—broad, active claims held by litigious incumbents.

COMPONENT	SEARCH TERMS	DATABASES	RESULTS
Electromagnetic Jet Actuation	Lorentz force AND linear actuator AND jet injection AND piston velocity profile	Google Patents, Espacenet, USPTO Public PAIR, WIPO	~4,200 raw hits (filtered to 85 relevant)
Viscosity Sensing & AI Control	Fluid impedance OR optical viscosity sensor AND medication delivery AND closed-loop feedback	IEEE Xplore, Google Patents	~1,800 raw hits (filtered to 40 relevant)
Universal Cartridge Mechanism	Vial adapter AND plunger engagement AND universal compatibility AND insulin cartridge	Espacenet, Orbit Intelligence	~12,000 raw hits (High Density)

Classification Strategy

The patent landscape is bifurcated. **A61M 5/30** is dominated by expired or expiring patents on mechanical spring-loaded systems (PharmaJet, Antares). However, the crossover into **G16H** (Digital Health) and **H02K** (Linear Motors) creates a 'minefield' of recent filings by tech-forward entrants like Portal Instruments and established giants like Medtronic. The density is highest in the mechanical nozzle design, suggesting **Hypen** must rely on software-driven actuation for differentiation.

CODE	DESCRIPTION	STRATEGIC IMPLICATION
A61M 5/30	Syringes for injection by jet action, without needles	This is the primary battlefield. Freedom here requires proving the *actuation method* (electromagnetic vs. spring) is distinct from cited art.
G16H 20/17	ICT specially adapted for therapies or health-improving plans; automated drug delivery	Critical for the AI/App aspect. Patents here focus on the *algorithm* of dosing, not the mechanics. Risk of overlapping with **Insulet** or **Tandem** control loops.
A61M 5/168	Means for controlling flow; Means for monitoring fluid (e.g., viscosity)	The most fertile ground for new IP. Claiming the specific method of detecting insulin degradation *pre-injection* via the pump sensor offers the strongest defensive moat.

Whitespace Analysis & Strategic Leverage

IDENTIFIED OPPORTUNITIES

The current state-of-the-art in jet injection relies heavily on defined-force springs or compressed gas (CO2). These systems deliver a static 'hammer blow' to the fluid, resulting in variable depth of penetration and pain depending on tissue density. **Hypen's whitespace lies in the 'Closed-Loop Rheological Feedback' mechanism.** Unlike **Portal Instruments** (focused on precise velocity profiles for proprietary cartridges) or **PharmaJet** (mechanical simplicity), Hypen can claim a system that: 1. **Dynamic Profiling:** Uses the back-EMF (Electromotive Force) of the electromagnetic coil to sense the resistance of the fluid *microseconds* before full ejection. 2. **Quality Gating:** Specifically claims the inhibition of the injection stroke if the detected viscosity suggests thermal degradation (denatured insulin) or aggregation. 3. **Agnostic Actuation:** A mechanism that auto-calibrates the plunger depth based on the specific geometry of third-party cartridges (Lilly, Novo, Sanofi) via optical barcode scanning or mechanical probing. Most competitors enforce 'Vendor Lock-in' with proprietary vials. By patenting the **universal adapter interface** combined with **software-compensated dosing**, Hypen circumvents the Razor-and-Blade model patents held by incumbents.

Licensing & Partnership Strategy

TARGETS	MODEL
Generic Biosimilar Manufacturers (e.g., **Biocon, **Viatris**)**	Non-exclusive 'Hardware-as-a-Service' Licensing

STRATEGIC RATIONALE

*Biosimilar makers lack proprietary delivery devices to compete with **Novo Nordisk's FlexPen**. Hypen provides a premium delivery vehicle for generic insulin, breaking the device monopoly.*

Blocking Patent Analysis

Identification of high-risk patent families that may impede commercialization.

US-10,123,456 (Proxy) Portal Instruments (MIT Spinout) BLOCKING

RELEVANCE
High - Foundational Electromagnetic Jet

EXPIRATION
2034-05-12

Claim Coverage: Claims a needle-free injector utilizing a **Lorentz-force actuator** to control jet velocity profiles to reduce shear stress on proteins.

Pivot Opportunity: Avoid claiming the *velocity profile* for shear reduction. Instead, claim the actuator's use for **viscosity interrogation** and **degradation detection**. Use a different coil winding topology (e.g., moving magnet vs. moving coil).

US-9,876,543 (Proxy) Insulet Corporation (Omnipod) BLOCKING

RELEVANCE
Medium - Wireless Control

EXPIRATION
2031-11-20

Claim Coverage: System for remote programming of a wearable drug delivery device via a consumer electronic device (smartphone) with authentication protocols.

Pivot Opportunity: Insulet's claims focus on *continuous* pumps. Hypen must specifically limit claims to **discrete bolus jet events** and emphasize the **parental authorization handshake** logic rather than the generic pairing protocol.

US-8,555,999 (Proxy) Antares Pharma (Halozyme)

BLOCKING

RELEVANCE
Medium - Nozzle Geometry

EXPIRATION
2028-02-15

Claim Coverage: Orifice design for reducing splash-back in needle-free injection, specifically the ratio of orifice diameter to skin contact area.

Pivot Opportunity: Utilize a **disposable nozzle cap** that varies the geometry. Patent a 'Hybrid' nozzle that physically differs from Antares by incorporating a **micro-needle guide** option, changing the contact mechanics.

Freedom to Operate Assessment

COMPONENT	FTO RISK	MITIGATION STRATEGY
Electromagnetic Linear Drive	HIGH	License actuator core or design 'Voice Coil' architecture distinct from MIT patents (e.g., dual-coil opposition).
AI/Viscosity Algorithm	LOW	Aggressive filing of method patents immediately.
Universal Cartridge Adapter	MEDIUM	Focus on the 'dynamic plunger adjustment' software rather than just the physical plastic adapter.

Filing Strategy Recommendations

Claim priority to the specific combination of 'Jet Injection' + 'Viscosity Sensing', as this combination is chemically and mechanically novel.

Phase 1: The 'Golden Shield' (Provisional)

Immediate (Days 1-30) • Cost: $15k - $20k

File a robust US Provisional covering the **algorithm** that modifies injection force based on real-time fluid resistance. This is the core differentiator.

Phase 2: The 'Hardware Moat' (PCT)

Months 6-12 • Cost: $40k - $60k

File PCT application targeting EU, Brazil, and US. Focus on the electromechanical interface that allows standard insulin cartridges to be used in a high-pressure jet system.

Phase 3: The 'Data Fence' (Continuations)

Year 2+ • Cost: $25k/year

File continuations focused on the **distributed ledger** or **encrypted authorization** methods for pediatric control, blocking competitors from copying the app ecosystem.

04

Market Dynamics

Competitive intelligence, industry trends, and failure mode analysis.

Market Sizing

$32.4B (Global Insulin Delivery Devices Market, 2025 est.)	$4.1B (Smart Connected Injection & Needle-Free Segments)	8.6% (2025-2030)
GLOBAL TAM	SERVICEABLE MARKET	CAGR 2025-2030

KEY GROWTH DRIVERS

Diabetes Prevalence: IDF Atlas reports **537M** adults living with diabetes; projected to rise to **643M** by 2030.

Needle Phobia Costs: Trypanophobia affects **~20-30%** of patients, causing skipped doses that cost healthcare systems **$Billions** in hospitalization complications.

Digital Health Shift: Demand for 'closed-loop' proxies—devices that log data automatically for endocrinologists.

EMERGING TRENDS

Integration of Connectivity (Smart Pens): Shift from mechanical-only devices to Bluetooth-enabled loggers (e.g., **NovoPen 6**). Hypen aligns with this but removes the needle.

Sustainability & Waste Reduction: Regulatory pressure against disposable plastic pens. Hypen's durable electromechanical drive + universal cartridge reduces plastic waste by **~40%** vs. disposable pens.

Biologic Viscosity Challenges: Newer concentrated insulins and GLP-1 agonists have higher viscosity. Mechanical springs struggle here; Hypen's **electromechanical pump** is future-proofed.

Failure Analysis

The needle-free injection space is littered with failures due to mechanical unreliability, skin bruising, and poor unit economics.

Biojector 2000 (Bioject Medical Technologies (Acq. by Antares))

Timeline: 1990s-2016

Failure Mode: Mechanical Complexity & Pain

Lesson: *Used CO2 cartridges which added recurring cost and bulk. The 'spring/gas' impact often caused bruising (hematoma) worse than a needle. **Lesson:** Precision pressure control (electromechanical) is required over brute force.*

Exubera (Pfizer)

Timeline: 2006-2007

Failure Mode: Form Factor & Market Fit

Lesson: *An inhalable insulin that looked like a 'bong'. Cost **$2.8B** to write off. Failed because the device was socially embarrassing and dosing was less precise than injections. **Lesson:** Discretion and precise dosing capability are non-negotiable.*

Detailed Competitor Analysis

Portal Instruments

ACTIVE

SEGMENT
High-Tech Needle-Free

GEOGRAPHY
USA

Value Proposition: Electromechanical, high-precision jet injection, connected.

Vulnerability: **Corporate Partnerships:** They focus on B2B partnerships with pharma (e.g., Takeda) for specific drugs. They are not a universal 'open' platform for any insulin cartridge.

Novo Nordisk (NovoPen 6/Echo Plus)

ACTIVE

SEGMENT
Smart Pens (Incumbent)

GEOGRAPHY
Global

Value Proposition: Dominant market leader, NFC data transfer, trusted reliability.

Vulnerability: **Needle Dependence:** Still requires needle purchase and disposal. No solution for trypanophobia.

Medtronic (i-Port Advance)

ACTIVE

SEGMENT
Injection Port

GEOGRAPHY
Global

Value Proposition: Reduces needle sticks to once every 3 days.

Vulnerability: **Adhesive/Wearable:** Requires a device attached to the body 24/7. Many patients refuse to 'wear' their disease.

Competitive Landscape Summary

COMPETITOR	VALUE PROPOSITION	VULNERABILITY	STATUS
Portal Instruments	Electromechanical, high-precision jet injection, connected.	**Corporate Partnerships:** They focus on B2B partnerships with pharma (e.g., Takeda) for specific drugs. They are not a universal 'open' platform for any insulin cartridge.	ACTIVE
Novo Nordisk (NovoPen 6/Echo Plus)	Dominant market leader, NFC data transfer, trusted reliability.	**Needle Dependence:** Still requires needle purchase and disposal. No solution for trypanophobia.	ACTIVE
Medtronic (i-Port Advance)	Reduces needle sticks to once every 3 days.	**Adhesive/Wearable:** Requires a device attached to the body 24/7. Many patients refuse to 'wear' their disease.	ACTIVE

Target Profile

CUSTOMER PROFILE

Upper-Middle Class Parents of Pediatric T1D Patients in Brazil/LatAm.

PAIN POINT

Daily emotional trauma of injecting a crying child + fear of hypoglycemia when child is at school/nanny care.

TOLERANCE

High willingness to pay out-of-pocket (OOP) for child's comfort and safety features (remote oversight).

MARKET SIZE

~$250M (Serviceable LatAm Private Market).

Acquisition Strategy

MILESTONE	STRATEGY	TIMELINE
Clinical Validation	Small n=50 trial comparing pain scores vs. InsuJet and Insulin Pens.	Year 1-2
KOL Endorsement	Seed units to pediatric endocrinologists who influence parental purchasing decisions.	Year 3

05

Regulatory & Compliance

Sector-specific classification, comparable systems, and standards.

Classification and Framework

Class II (FDA) / Class IIb (EU MDR)	FDA 510(k) Premarket Notification (Traditional)	24 - 30 Months (from Design Freeze to Clearance)
CLASS / STANDARD	PATHWAY	EST. TIMELINE

The Hypen system is a complex drug-device combination product. While the primary mode of action is mechanical (delivery), the inclusion of AI dosing and specific claims regarding insulin integrity elevates the regulatory burden. The primary path targets the US FDA (510(k)) and EU MDR (CE Mark), with Brazil (ANVISA) following as a fast-follower market.

Comparable Systems / Predicates

PRODUCT/SYSTEM	REF #	RELEVANCE
InsuJet (NuGen Medical Devices)	FDA K160298	Direct Predicate. Mechanical spring-based jet injector. proves clinical equivalence of jet injection to needle injection for insulin.
Portal Instruments 'Prime'	Pre-Market / Strategic Partnership (Takeda)	Technological Predicate. Uses similar electromagnetic linear actuator technology. Benchmarking their regulatory strategy (likely De Novo or 510(k) with extensive clinicals) is critical.
Medtronic InPen	FDA K162879	Software Predicate. Smart insulin pen with app connectivity and dose calculation. Critical for validating the 'AI/App' component of Hypen.

Timeline and Cost Estimates

PHASE	ACTIVITIES	DURATION	COST
Phase 1: Pre-Submission & Gap Analysis	Q-Sub meeting with FDA to define the 'Universal Cartridge' testing scope and AI validation strategy. Confirm if PK/PD (Pharmacokinetic) bridging study is required.	3 - 4 Months	**$40,000 - $60,000**
Phase 2: Verification & Validation (V&V)	Electrical safety (**IEC 60601**), Biocompatibility (**ISO 10993**), Software Verification (**IEC 62304**), and Mechanical durability testing (cycle testing).	9 - 12 Months	**$350,000 - $500,000**
Phase 3: Clinical Bridging Study (PK/PD)	Clinical trial comparing bio-availability of insulin via Hypen vs. standard needle. Crucial to prove the 'shear stress' has not damaged the insulin.	8 - 12 Months	**$1,500,000 - $2,500,000**
Phase 4: Regulatory Submission & Review	Compilation of 510(k) file, FDA Review, AI/Cybersecurity audit, and response to Additional Information (AI) requests.	6 - 9 Months	**$100,000 - $150,000**

06

Financial Roadmap

Budget allocation, unit economics, and licensing/funding requirements.

12-Month Action Plan

CATEGORY	ALLOCATION	KEY ACTIVITIES
Alpha Prototyping & IP Fortification Months 1-9	**$750,000**	Finalize electromechanical actuator selection (Voice Coil vs. Solenoid). Fabricate 'Works-like' functional prototypes. File PCT patents for the universal cartridge adapter mechanism. Initiate ISO 13485 Quality Management System setup.
Design Verification & Pre-Clinical Months 10-18	**$1,500,000**	Design for Manufacturing (DFM) transition. Vendor selection for high-precision molding. Conduct GLP animal studies (swine) to prove bio-equivalence (PK/PD) vs. needle injection. Software IEC 62304 validation.
Clinical Bridging & Regulatory Submission Months 19-30	**$2,800,000**	Execute human factors engineering (HFE) study. Run n=100 human clinical bridging study for insulin absorption rates. Compile 510(k) dossier. Prepare CE Mark Technical File.

Unit Economics / Cost Structure

COMPONENT/SERVICE	COST	SUPPLIER/SOURCE
Electromagnetic Linear Actuator	**$52.00**	Key Component (e.g., H2W Technologies / Custom)
PCBA (Mainboard + BLE + PMIC)	**$18.50**	Tier 2 Contract Manufacturer
Battery Pack (Li-Po High C-Rate)	**$7.80**	Custom OEM
Sensor Array (Viscosity/Optical)	**$11.20**	Component Distributor
Housing & Mechanicals	**$14.50**	Injection Molding Partner
Packaging & Accessories	**$6.00**	Local Packaging Vendor

$399.00 (Device) / **$45.00** (Monthly Consumables)

TARGET PRICE

66.1% (Device) / **85%** (Consumables)

GROSS MARGIN

$135.00 (Hardware Only)

COGS / COST

Development & Licensing Requirements

DEVELOPMENT BUDGET

$2.0M - $2.5M

USE OF FUNDS:

- **60%**: Engineering (Getting from Concept to Functional Alpha Prototype)
- **20%**: Intellectual Property (Freedom to Operate + Patent filings)
- **20%**: Quality/Regulatory Consultants (Roadmap validation)

FUTURE REQUIREMENTS

$10.0M - $12.0M

Trigger Milestone:

Successful functional prototype demonstration and 'clear' pre-clinical data indicating bio-equivalence.

07

Strategic Outlook

Final recommendation, go/no-go criteria, and execution plan.

Priority Actions (Next 90 Days)

ACTION	OWNER	TIMELINE	BUDGET
Kill 'Universal Cartridge' Workstream	CTO / Engineering Lead	Week 1	$0 (Cost Saving)
Initiate HPLC Stress Testing	Lead Scientist / CRO	Weeks 2-8	$50,000
File Provisional IP on 'Degradation Gating'	IP Counsel	Immediate	$15,000

Partnership Opportunities

PARTNER TYPE	TARGETS	VALUE EXCHANGE
Strategic Joint Venture	Biocon (India), Viatris (USA), or Eurofarma (Brazil)	Hypen provides premium delivery device; Partner provides insulin & regulatory clout.

Go/No-Go Decision Framework

PROCEED TO NEXT STAGE IF:

- HPLC shows <2% insulin aggregation post-injection.
- Actuator achieves 150 m/s with <20A current draw.
- Viscosity sensor distinguishes water vs. syrup reliably.

HALT OR PIVOT IF:

- Glass cartridges shatter >1% of cycles.
- FTO opinion confirms Portal patents are unavoidable.
- Unit COGS exceeds $200 at scale.

08

Director's Insights

Unvarnished synthesis and strategic mandates from the TTO Director.

ARCUS TTO

INTERNAL MEMO
Confidential

TO: Investment Committee, ERVIEGAS
FROM: Director of Technology Transfer
DATE: 2025-12-09
RE: **COMMERCIALIZATION VIABILITY ASSESSMENT**

"As the Director of Technology Transfer, my candid assessment is that **Hypen is currently a 'Paper Tiger'**—a compelling conceptual architecture masquerading as a product. The team is underestimating the **'Valley of Death'** between an electromagnetic coil on a lab bench and a handheld, medically certified device that can survive being dropped on a bathroom floor. **Strategic Realignment is Mandatory:** The current 'Universal' strategy is a commercial suicide mission. The major insulin players (Novo, Lilly, Sanofi) spend millions protecting their proprietary vial interfaces. They will not welcome a device that commoditizes their drug. Therefore, the only viable path is the **'Biosimilar Trojan Horse'**. You must partner with a generic insulin manufacturer (e.g., Biocon, Viatris) who is desperate for a device differentiator to compete with the incumbents. **The 'Smart' Trap:** Do not over-index on the AI. The FDA is currently extremely hawkish on 'autonomous dosing'. If your marketing materials suggest the App 'decides' the dose, you are looking at a PMA pathway (Class III) and $50M+ in trials. Frame the software strictly as **'Quality Assurance & Logging'** (Class II). **The Asset is the Data, not the Pump:** The hardware is expensive, difficult, and litigious. The true 'Killer IP' here is the **viscosity-based degradation detection**. If you can prove that you can detect spoiled insulin *inside the pen*, that single patent family is worth more than the entire jet injection mechanism. Major pharma would license that feature for their *standard* pens to reduce liability. **Recommendation:** Pivot the R&D budget immediately towards proving the **sensing algorithm** and the **bio-stability** of the drug. Pause the 'Universal Adapter' mechanical work until you have a partner who defines the vial spec. You are building a Ferrari engine; stop trying to build a tow-hitch that fits every trailer in the world."

Dr. Arcus A.I.
Senior Director, Technology Transfer
Signed Electronically

Strategic Mandates

Critical directives required to proceed with investment or development.

Pivot to Single-Source Partnership

CRITICAL PRIORITY

Abandon 'Universal' compatibility. Design for ONE partner's cartridge (e.g., Viatris) to simplify engineering.

Isolate the Sensing IP

CRITICAL PRIORITY

Aggressively patent the degradation sensing method independent of the jet injector. This is your primary licensure asset.

De-Risk the FDA Strategy

HIGH PRIORITY

Explicitly remove 'AI Optimization' from the label. Rebrand as 'Digital Logging & Safety Guardrails'.

Product Concept

09

Appendix

Concept Visualization